"OMRON receives FDA authorisation for blood pressure monitors with AFib feature" was originally created and published by ...

The FDA has granted a de novo clearance to a wearable device—with a form factor you’re familiar with—that can check patients ...

AFib is the most common type of heart arrythmia 2. Left untreated, it increases risk of stroke, heart failure, myocardial ...

Assessing when to initiate anticoagulation in atrial fibrillation is not improved by including gender, says the ESC in their ...

Late last month, Boston Scientific announced it was pausing a study examining pulsed field ablation as a first-line therapy.

Atrial arrhythmias were found in 26% of patients with sickle cell disease (SCD), with a significant association with stroke history. Early detection and treatment of atrial arrhythmias may help ...

Fourth Frontier, a medical technology company based out of New York and Bangalore, announced the 510(k) clearance of the ...

Fourth Frontier has achieved a crucial milestone with the FDA's clearance of the Frontier X Plus, a single-lead ECG monitor. Positioned to enhance heart health monitoring, this wearable device ...

OMRON Healthcare has received de novo authorization from the U.S. Food and Drug Administration (FDA) to market new home blood pressure monitors featuring AI-powered atrial fibrillation ...

Atrial fibrillation (AF) often remains undiagnosed and independently ... adults screening for undiagnosed atrial AF using a 14-day electrocardiographic (ECG) monitor to reduce stroke. They conducted ...

allow for continuous monitoring of heart rhythms. These innovations improve patient outcomes by enabling timely interventions and reducing hospitalizations, thereby increasing demand for these devices ...

"The purpose of this trial is to better understand how to personalize anticoagulation safely and effectively, especially for ...